Abstract
The incidence of venous and arterial thrombosis in a placebo-controlled randomised trial of DN-101 (high dose calcitriol) with docetaxel versus docetaxel was compared. Of the 13 thrombotic events observed in the 250 patients enroled in this study, two occurred in DN-101 and 11 in placebo-treated patients (P = 0.01). This difference remained significant after adjustment for baseline history of thrombosis, atrial fibrillation and use of anti-thrombotic agents. In vitro and vitamin D receptor (VDR) knockout mouse studies predict that nanomolar concentrations of calcitriol may act as an antithrombotic agent. We report the first clinical observation that supports this hypothesis in humans.
Original language | English (US) |
---|---|
Pages (from-to) | 392-394 |
Number of pages | 3 |
Journal | British Journal of Haematology |
Volume | 135 |
Issue number | 3 |
DOIs | |
State | Published - Nov 2006 |
Keywords
- Calcitriol
- Prostate cancer
- Thromboembolism
- Thrombosis
- Vitamin D
ASJC Scopus subject areas
- Hematology